Asia Pacific Single-Cell Analysis Market - Government Support For Cell-Based Research To Drive The Adoption Of Microscopes
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
Summary
- The academic & research laboratories segment accounted for the largest share.
- Animal cells segment to register the highest growth rate during the forecast period.
The rising incidence of infectious diseases, increasing pandemics frequency, increasing R&D in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the rising prevalence of cancer are the major factors driving the growth of Asia Pacific single-cell analysis market. However, the high cost of single-cell analysis products is a major factor hampering the growth of the Asia Pacific single-cell analysis market. Emerging economies such as Japan and China are providing lucrative opportunities for the players operating in the APAC single-cell analysis market.
How the Market Looks Like?
Predicted to grow at a CAGR of 20.1% during the forecast period, the global Asia Pacific Single-cell Analysis Market is estimated to reach $1,375 million by 2025. Japan to witness the highest growth during the forecast period.
Based on product, the Asia Pacific single-cell analysis market is segmented into consumables and instruments. The consumables segment accounted for the largest share of the APAC single-cell analysis market in 2019. The frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in research and genetic exploration, exosome analysis, and isolation of RNA and DNA are the major factors driving this segments growth.
Based on end-user, the APAC single-cell analysis market is segmented into academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers. In 2019, the academic & research laboratories segment accounted for the largest share of the APAC single-cell analysis market. The increasing funding for life science research, increasing number of medical colleges and universities, and the increasing number of collaborations among research institutes and life science research companies are the major factors driving the growth of this end-user segment.
Trend: Integration of microfluidics in single-cell analysis;
Currently, the isolation and analysis of circulating tumor cells (CTCs) and cells that are present in low quantities in the body is a major challenge faced by researchers and clinicians. Advances in microfluidics technology have provided robust solutions for the isolation and analysis of single cells. Moreover, microfluidic chips are easy to use and provide reliable and efficient isolation of single cells from a small sample volume.
Microfluidics has various advantages in single-cell analysis, including reduced reagent consumption, increased throughput, and ease of efficient automation. Citing the potential of this technology in single-cell analysis, various research studies are being performed for evaluating the performance of microfluidic chips in analyzing other types of cells.Download PDF Brochure @ Download PDF Brochure - APAC Single-cell Analysis Market - Global Forecast to 2025 | MarketsandMarkets
What Drives the Market?
The growth of the global market for Asia Pacific Single-cell Analysis is primarily influenced by the following factors:
- Rising prevalence of cancer
- Increasing R&D in the pharmaceutical and biotechnology industries for complex diseases
- Growth in stem cell research
- Growing focus on personalized medicine
- High growth potential of single-cell sequencing
Read more about Asia Pacific Single-cell Analysis Market: APAC Single-cell Analysis Market - Global Forecast to 2025 | MarketsandMarkets
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.